Newborn screening

Complexities in universal genetic testing

Nancy S. Green, Siobhan M. Dolan, Thomas H. Murray

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Newborn screening (NBS)-in which each newborn infant is screened for up to 50 specific metabolic disorders for early detection and intervention-is the first program of populationwide genetic testing. As a public health intervention, NBS has greatly improved the lives of thousands of affected children. New technologies and new economic and social forces pose significant ethical and clinical challenges to NBS. Two primary challenges concern (1) accommodating clinical and ethical standards to rapid technological developments in NBS and (2) preparing public health systems to respond to the medical advances and social forces driving expansion of NBS programs. We describe and analyze these challenges through consideration of 3 disorders: phenylketonuria, medium-chain acyl-CoA dehydrogenase deficiency, and cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)1955-1959
Number of pages5
JournalAmerican Journal of Public Health
Volume96
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Genetic Testing
Newborn Infant
Public Health
Phenylketonurias
Cystic Fibrosis
Economics
Technology

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Newborn screening : Complexities in universal genetic testing. / Green, Nancy S.; Dolan, Siobhan M.; Murray, Thomas H.

In: American Journal of Public Health, Vol. 96, No. 11, 11.2006, p. 1955-1959.

Research output: Contribution to journalArticle

Green, Nancy S. ; Dolan, Siobhan M. ; Murray, Thomas H. / Newborn screening : Complexities in universal genetic testing. In: American Journal of Public Health. 2006 ; Vol. 96, No. 11. pp. 1955-1959.
@article{3d81472d31d74cb5b34456ba695f7078,
title = "Newborn screening: Complexities in universal genetic testing",
abstract = "Newborn screening (NBS)-in which each newborn infant is screened for up to 50 specific metabolic disorders for early detection and intervention-is the first program of populationwide genetic testing. As a public health intervention, NBS has greatly improved the lives of thousands of affected children. New technologies and new economic and social forces pose significant ethical and clinical challenges to NBS. Two primary challenges concern (1) accommodating clinical and ethical standards to rapid technological developments in NBS and (2) preparing public health systems to respond to the medical advances and social forces driving expansion of NBS programs. We describe and analyze these challenges through consideration of 3 disorders: phenylketonuria, medium-chain acyl-CoA dehydrogenase deficiency, and cystic fibrosis.",
author = "Green, {Nancy S.} and Dolan, {Siobhan M.} and Murray, {Thomas H.}",
year = "2006",
month = "11",
doi = "10.2105/AJPH.2005.070300",
language = "English (US)",
volume = "96",
pages = "1955--1959",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "11",

}

TY - JOUR

T1 - Newborn screening

T2 - Complexities in universal genetic testing

AU - Green, Nancy S.

AU - Dolan, Siobhan M.

AU - Murray, Thomas H.

PY - 2006/11

Y1 - 2006/11

N2 - Newborn screening (NBS)-in which each newborn infant is screened for up to 50 specific metabolic disorders for early detection and intervention-is the first program of populationwide genetic testing. As a public health intervention, NBS has greatly improved the lives of thousands of affected children. New technologies and new economic and social forces pose significant ethical and clinical challenges to NBS. Two primary challenges concern (1) accommodating clinical and ethical standards to rapid technological developments in NBS and (2) preparing public health systems to respond to the medical advances and social forces driving expansion of NBS programs. We describe and analyze these challenges through consideration of 3 disorders: phenylketonuria, medium-chain acyl-CoA dehydrogenase deficiency, and cystic fibrosis.

AB - Newborn screening (NBS)-in which each newborn infant is screened for up to 50 specific metabolic disorders for early detection and intervention-is the first program of populationwide genetic testing. As a public health intervention, NBS has greatly improved the lives of thousands of affected children. New technologies and new economic and social forces pose significant ethical and clinical challenges to NBS. Two primary challenges concern (1) accommodating clinical and ethical standards to rapid technological developments in NBS and (2) preparing public health systems to respond to the medical advances and social forces driving expansion of NBS programs. We describe and analyze these challenges through consideration of 3 disorders: phenylketonuria, medium-chain acyl-CoA dehydrogenase deficiency, and cystic fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=33750493316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750493316&partnerID=8YFLogxK

U2 - 10.2105/AJPH.2005.070300

DO - 10.2105/AJPH.2005.070300

M3 - Article

VL - 96

SP - 1955

EP - 1959

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 11

ER -